LCI699

DRUG6 trials

Sponsors

Novartis, Novartis Pharmaceuticals, RECORDATI GROUP

Conditions

Cushing DiseaseCushing SyndromeCushings DiseaseEssential HypertensionHypertensionPrimary Hyperaldosteronism

Phase 2

Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism

CompletedNCT00732771

NovartisPrimary Hyperaldosteronism

Start: 2008-06-30Target: 12Updated: 2009-08-26

A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension

CompletedNCT00758524

Novartis PharmaceuticalsEssential Hypertension

Start: 2008-09-11End: 2009-07-02Updated: 2021-07-06

A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension

CompletedNCT00817635

NovartisHypertension

Start: 2008-12-22End: 2009-10-13Updated: 2021-06-02

A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension

CompletedNCT00817414

NovartisHypertension

Start: 2009-01-14End: 2009-08-12Updated: 2021-06-02

Safety and Efficacy of LCI699 in Cushing's Disease Patients

CompletedNCT01331239

Novartis PharmaceuticalsCushing Disease, Cushings Disease

Start: 2011-03-23End: 2019-10-22Updated: 2021-01-22

Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

RecruitingNCT03708900

RECORDATI GROUPCushing Syndrome

Start: 2021-04-28End: 2027-07-21Target: 12Updated: 2026-03-27

Related Papers

Osilodrostat dose impact on efficacy/safety in Cushing's disease: large, pooled analysis of LINC 2, 3, and 4.

2025-10-011 citations

12275 Effect Of Osilodrostat On Cardiovascular And Metabolic Manifestations Of Hypercortisolism In Patients With Non-Pituitary Cushing’s Syndrome: Findings From A Retrospective Observational Study (LINC 7)

Journal of the Endocrine Society2024-10-012 citations

SAT-671 Safety And Effectiveness Of Osilodrostat In Patients With Non-Pituitary Cushing’s Syndrome: Results From The Retrospective Observational LINC 7 Study

Journal of the Endocrine Society2024-10-01

THU038 Osilodrostat Dosing In Cushing’s Disease: A Pooled Analysis Of The LINC Program

Journal of the Endocrine Society2023-10-01

Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2).

2022-10-1127 citations

Osilodrostat for Cushing Disease and Its Role in Pediatrics.

2022-01-196 citations

SUN-454 Rationale and Methods for a Phase II Trial Evaluating Osilodrostat in Pediatric Patients with Cushing's Disease

Journal of the Endocrine Society2019-04-01

Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.

2016-04-01111 citations

Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial.

2011-10-10153 citations